Skip to content

Influence of Superficial Parasternal Intercostal Plane Block on Internal Thoracic Artery Caliber to Facilitate Surgical Harvesting in CABG

Influence of Superficial Parasternal Intercostal Plane Block on Internal Thoracic Artery Caliber to Facilitate Surgical Harvesting in CABG

Status
Not yet recruiting
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07663435
Acronym
IMA CABG PIPB
Enrollment
50
Registered
2026-06-23
Start date
2026-07-01
Completion date
2026-12-31
Last updated
2026-06-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

CABG Graft Integrity, Pain Management, Parasternal Block

Keywords

IMA, CABG, SPIPB

Brief summary

Influence of Superficial Parasternal Intercostal Plane Block (SPIPB) on Internal Thoracic Artery (ITA) Caliber and Surgical Harvesting Efficiency in Coronary Artery Bypass Grafting (CABG)

Detailed description

Parasternal intercostal blocks (PSB) represent a newer approach to post-sternotomy pain management. Studies suggest their effectiveness in providing postoperative analgesia , with a significant advantage being their suitability even during concurrent antiplatelet or anticoagulant therapy.In addition to its sympatholytic effects cause vasodilatation , a reduction in vascular resistance, and an increase in local blood flow . The effects are maintained up to the early postoperative period .

Interventions

DRUGBupivacaine

Superficial parasternal block will be given to assess diameter of IMA by using US to assess caliber and ease of harvesting.

Sponsors

Ain Shams University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Subject)

Intervention model description

Receive parasternal block

Eligibility

Sex/Gender
ALL
Age
22 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* • Age group: Adult patients from age of 22 to 65 years. * Sex: Both sexes * Patients undergoing CABG with IMA harvesting

Exclusion criteria

* • Patients with pre-existing active bloodstream infection or systemic infection * Refuse consent * IMA graft not suitable * Morbidly obese (BMI \> 40 ) * Hemodynamic instability * Severe pulmonary disease * Previous thoracic surgeries (makes it difficult to harvest IMA) * Advanced malignancy or chronic disease with life expectancy less than six months * Emergency surgery

Design outcomes

Primary

MeasureTime frameDescription
Change in Internal Thoracic Artery (ITA) DiameterMeasured 15 minutes after the SPIPB injection by intraoperative ultrasound.Change in the diameter of the Internal Thoracic Artery (ITA) measured in millimeters (mm) after SPIPB administration.
Change in Internal Thoracic Artery (ITA) Cross-Sectional AreaMeasured 15 minutes after the SPIPB injection by Intraoperative ultrasound.Change in the cross-sectional area of the Internal Thoracic Artery (ITA) measured in square millimeters (mm²) after SPIPB administration.

Secondary

MeasureTime frameDescription
Time Required for ITA HarvestingMeasured during the surgical harvesting procedure.Total time in minutes (min) required to harvest the Internal Thoracic Artery.
Technical Difficulty of ITA HarvestingAssessed by the surgeon immediately after the harvesting procedure.Assessed using a Technical Difficulty Scale. The scale ranges from 1 (Very Easy) to 5 (Very Difficult), where a higher score indicates a worse outcome (more difficult harvesting).
Postoperative Pain ScoreMeasured at 24 hours postoperatively.Postoperative pain assessed using the Visual Analog Scale (VAS) for pain. The scale ranges from 0 mm (No Pain) to 100 mm (Worst Possible Pain), where a higher score indicates a worse outcome.
Postoperative Opioid ConsumptionMeasured over the first 24 hours postoperatively.Total postoperative opioid consumption, measured in Morphine Milligram Equivalents (MME).
Intraoperative Hemodynamic StabilityMeasured during the intraoperative period.Incidence of significant hemodynamic instability (e.g., episodes of hypotension or hypertension requiring intervention).

Countries

Egypt

Contacts

CONTACTSarah hamdy Elghareeb, MD
sarahhamdy@med.asu.edu.eg+201012434690
PRINCIPAL_INVESTIGATORSarah H Elghareeb, MD

Ain Shams

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 24, 2026